Literature DB >> 22955018

Racial differences between blacks and whites with systemic sclerosis.

Richard M Silver1, Galina Bogatkevich, Elena Tourkina, Paul J Nietert, Stanley Hoffman.   

Abstract

PURPOSE OF REVIEW: Racial disparities appear to exist in the susceptibility and severity of systemic sclerosis (SSc, scleroderma) and are responsible for a greater health burden in blacks as compared with whites. Disparities in socioeconomic status and access to healthcare do not sufficiently explain the observed differences in prevalence and mortality. It is important to determine whether there might be a biologic basis for the racial disparities observed in SSc. RECENT
FINDINGS: We present data to suggest that the increased susceptibility and severity of SSc in blacks may result in part from an imbalance of profibrotic and antifibrotic factors. Racial differences in the expression of transforming growth factor-β1 (TGF-β1) and caveolin-1, as well as differences in the expression of hepatocyte growth factor and PPAR-γ, have been demonstrated in blacks with SSc, as well as in normal black individuals. A genetic predisposition to fibrosis may account for much of the racial disparities between black and white patients with SSc.
SUMMARY: A better understanding of the biologic basis for the racial disparities observed in SSc may lead to improved therapies, along with the recognition that different therapies may need to be adapted for different groups of patients.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22955018      PMCID: PMC3756312          DOI: 10.1097/BOR.0b013e328356d9dc

Source DB:  PubMed          Journal:  Curr Opin Rheumatol        ISSN: 1040-8711            Impact factor:   5.006


  58 in total

1.  Caveolin interaction with protein kinase C. Isoenzyme-dependent regulation of kinase activity by the caveolin scaffolding domain peptide.

Authors:  N Oka; M Yamamoto; C Schwencke; J Kawabe; T Ebina; S Ohno; J Couet; M P Lisanti; Y Ishikawa
Journal:  J Biol Chem       Date:  1997-12-26       Impact factor: 5.157

2.  HGF reduces advancing lung fibrosis in mice: a potential role for MMP-dependent myofibroblast apoptosis.

Authors:  Shinya Mizuno; Kunio Matsumoto; Ming-Yue Li; Toshikazu Nakamura
Journal:  FASEB J       Date:  2005-01-21       Impact factor: 5.191

3.  Serum levels of interleukin-6 and interleukin-10 correlate with total skin thickness score in patients with systemic sclerosis.

Authors:  S Sato; M Hasegawa; K Takehara
Journal:  J Dermatol Sci       Date:  2001-10       Impact factor: 4.563

4.  Antifibrotic properties of caveolin-1 scaffolding domain in vitro and in vivo.

Authors:  Elena Tourkina; Mathieu Richard; Pal Gööz; Michael Bonner; Jaspreet Pannu; Russell Harley; Pascal N Bernatchez; William C Sessa; Richard M Silver; Stanley Hoffman
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2008-01-18       Impact factor: 5.464

5.  Patterns of hospital admissions and emergency room visits among patients with scleroderma in South Carolina, USA.

Authors:  Paul J Nietert; Richard M Silver
Journal:  J Rheumatol       Date:  2003-06       Impact factor: 4.666

6.  Mechanisms of pathogenesis in scleroderma. I. Overproduction of interleukin 6 by fibroblasts cultured from affected skin sites of patients with scleroderma.

Authors:  C A Feghali; K L Bost; D W Boulware; L S Levy
Journal:  J Rheumatol       Date:  1992-08       Impact factor: 4.666

7.  Impairment of the antifibrotic effect of hepatocyte growth factor in lung fibroblasts from African Americans: possible role in systemic sclerosis.

Authors:  Galina S Bogatkevich; Anna Ludwicka-Bradley; Kristin B Highland; Faye Hant; Paul J Nietert; C Beth Singleton; Carol A Feghali-Bostwick; Richard M Silver
Journal:  Arthritis Rheum       Date:  2007-07

8.  Ethnic disparities among patients with pulmonary hypertension associated with systemic sclerosis.

Authors:  Ashley D Beall; Paul J Nietert; Marian H Taylor; Holly C Mitchell; Stephanie R Shaftman; Richard M Silver; Edwin A Smith; Marcy B Bolster
Journal:  J Rheumatol       Date:  2007-05-15       Impact factor: 4.666

9.  A clinical and serologic comparison of African American and Caucasian patients with systemic sclerosis.

Authors:  Virginia Steen; Robyn T Domsic; Mary Lucas; Noreen Fertig; Thomas A Medsger
Journal:  Arthritis Rheum       Date:  2012-09

10.  Transforming growth factor-beta 1 hyperexpression in African-American hypertensives: A novel mediator of hypertension and/or target organ damage.

Authors:  M Suthanthiran; B Li; J O Song; R Ding; V K Sharma; J E Schwartz; P August
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-28       Impact factor: 11.205

View more
  13 in total

Review 1.  Interstitial lung disease in systemic sclerosis: current and future treatment.

Authors:  Roberto Giacomelli; Vasiliki Liakouli; Onorina Berardicurti; Piero Ruscitti; Paola Di Benedetto; Francesco Carubbi; Giuliana Guggino; Salvatore Di Bartolomeo; Francesco Ciccia; Giovanni Triolo; Paola Cipriani
Journal:  Rheumatol Int       Date:  2017-01-06       Impact factor: 2.631

2.  Clinical and laboratory features of African-Brazilian patients with systemic sclerosis.

Authors:  Cristiane Mendes; Vilma S T Viana; Sandra G Pasoto; Elaine P Leon; Eloisa Bonfa; Percival D Sampaio-Barros
Journal:  Clin Rheumatol       Date:  2019-05-07       Impact factor: 2.980

3.  Comparison of the clinical phenotype of systemic sclerosis patients in Iran and France in two university centers.

Authors:  Yannick Allanore; Farhad Gharibdoost; Ahmad Reza Jamshidi; Ali Javinani; Jérôme Avouac; Elnaz Rastkar; Sadid Hooshmandi; Hoda Kavosi
Journal:  J Scleroderma Relat Disord       Date:  2018-11-20

Review 4.  Recent advances in understanding the pathogenesis of scleroderma-interstitial lung disease.

Authors:  Tanjina Akter; Richard M Silver; Galina S Bogatkevich
Journal:  Curr Rheumatol Rep       Date:  2014-04       Impact factor: 4.592

5.  Caveolin-1 deficiency may predispose African Americans to systemic sclerosis-related interstitial lung disease.

Authors:  Charles Reese; Beth Perry; Jonathan Heywood; Michael Bonner; Richard P Visconti; Rebecca Lee; Corey M Hatfield; Richard M Silver; Stanley Hoffman; Elena Tourkina
Journal:  Arthritis Rheumatol       Date:  2014-07       Impact factor: 10.995

Review 6.  Management of Systemic-Sclerosis-Associated Interstitial Lung Disease.

Authors:  Katherine Culp Silver; Richard M Silver
Journal:  Rheum Dis Clin North Am       Date:  2015-05-23       Impact factor: 2.670

7.  Ethnic differences in TGFβ-signaling pathway may contribute to prostate cancer health disparity.

Authors:  Bethtrice Elliott; DeAdra L Zackery; Vanessa A Eaton; Re'Josef T Jones; Fisseha Abebe; Camille C Ragin; Shafiq A Khan
Journal:  Carcinogenesis       Date:  2018-04-05       Impact factor: 4.944

8.  Differences in synovial fibrosis relative to range of motion in knee osteoarthritis patients.

Authors:  Sydney Hodgeson; Sarah O'Brien; Jennifer Simkin; Elena Plakotaris; Christina McCarthy; Vinod Dasa; Luis Marrero
Journal:  J Orthop Res       Date:  2021-05-11       Impact factor: 3.494

9.  D1398G Variant of MET Is Associated with Impaired Signaling of Hepatocyte Growth Factor in Alveolar Epithelial Cells and Lung Fibroblasts.

Authors:  Ilia Atanelishvili; Yuichiro Shirai; Tanjina Akter; Atsushi Noguchi; Kurt T Ash; Suniti Misra; Sibnath Ghatak; Richard M Silver; Galina S Bogatkevich
Journal:  PLoS One       Date:  2016-09-01       Impact factor: 3.240

10.  Clinical and serological features of systemic sclerosis in a multicenter African American cohort: Analysis of the genome research in African American scleroderma patients clinical database.

Authors:  Nadia D Morgan; Ami A Shah; Maureen D Mayes; Robyn T Domsic; Thomas A Medsger; Virginia D Steen; John Varga; Mary Carns; Paula S Ramos; Richard M Silver; Elena Schiopu; Dinesh Khanna; Vivien Hsu; Jessica K Gordon; Heather Gladue; Lesley A Saketkoo; Lindsey A Criswell; Chris T Derk; Marcin A Trojanowski; Victoria K Shanmugam; Lorinda Chung; Antonia Valenzuela; Reem Jan; Avram Goldberg; Elaine F Remmers; Daniel L Kastner; Fredrick M Wigley; Pravitt Gourh; Francesco Boin
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.